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M14th International Congress on Infectious Diseases (ICID) Abs
that clinical care will not be harmed by control measures
such as: de-escalation of therapy, dose optimization, and
parenteral to oral conversion of antimicrobials with excel-
lent bioavailability can decrease the length of hospital stay
and health care costs.
doi:10.1016/j.ijid.2010.02.2185
61.004
New Antibiotics: Which Role in a Antimicrobial Steward-
ship Program?
D. Curcio
Hospital de Infecciosas F.J. Muniz, Buenos Aires, Argentina
Infections caused by multidrug-resistant bacteria con-
tinue to challenge physicians in the daily practice. We
face growing resistance among Gram-positive and Gram-
negative pathogens that cause infection in the hospital
and in the community. Rice recently reported these as
the ‘‘ESKAPE’’ pathogens (Enterococcus faecium, Staphy-
lococcus aureus, Klebsiella pneumoniae, Acinetobacter
baumanii, Pseudomonas aeruginosa, and Enterobacter
species) to emphasize that they currently cause the majority
of world-wide hospital infections and effectively ‘‘escape’’
the effects of antibacterial drugs.
In this context, controlling antibiotic use and bacterial
resistance trough an antibiotic stewardship program (ASP)
is of major importance to all professionals involved in infec-
tious diseases.
A critical need to develop new antimicrobial compounds
and to use the recently approved agents appropriately are
components of all ASP. Unfortunately, most of the agents
which are in the late stage of develop have activity only
against Gram-positives and none is active for treatment of
infections caused by the Gram-negative ESKAPE pathogens.
We have analized the body of the literature with the aim
to deﬁne, within a ASP, the opportunity of use and the poten-
tial advantages of new antibiotics in order to reduce the
emergence and selection of resistant pathogens.
Related with the role of the new antibiotics in a Asp, it is
possible to consider the following points: i-the use of tige-
cycline instead of carbapenems in clinical settings with high
rates of carbapenems-resistant pathogens (ie. in nosocomial
peritonitis), ii-the use of doripenem in extended-infusion
(ie. in severe infections due to Pseudomonas aeruginosa);
iii-the use of daptomycin at high doses (ie. in infections
due to methicillin-resistant Staphylococcus aureus) and iv-
the use of ceftobiprole as empiric monotherapy (ie. in some
suspected mixed infections).
The use of the new antibiotics in the daily practice
based on the individual patient characteristics, causative
organism, site of infection, and pharmacokinetic and phar-
macodynamic characteristics of the drug is an important
part of an ASP.
doi:10.1016/j.ijid.2010.02.2186
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urrent challenges in HIV care (Invited Presenta-
ion)
2.001
tate of the Art on ARV Therapy: How Many Standards of
are?
. Cahn
Foundation Huesped, Buenos Aires, Argentina
Albeit nobody would support the idea of ‘‘ﬁrst and second
lass medicine’’, in real life we confront AIDS with at leat
wo standards of care. When to start ARV therapy remains a
atter of debate. No disagreement exists for symptomatic
atients, as well as for asymptomatic individuals with CD4
ounts of 350/ mm3 or below. In resource-poor settings,
HO recommended until late 2009 that adolescents and
dults should start HAART when they have advanced HIV
isease, mildly symptomatic and asymptomatic disease,
HO Stage II or I HIV disease with CD4 counts <200/mm3
These recommendations were updated in November 2009
nd look now closer to those released by other interna-
ional bodies. Some Western countries guidelines panels,
ike the DHHS recommends now treatment initiation in
symptomatic patients when the CD4 count falls below
50/mm3, and have shown a divided opinion regarding the
f treatment should be considered in patients with CD4
ell counts <500/mm3, particularly if the patient has high
iral load, age above 50 and/or comorbidities like HBV or
CV coinfections, among others. Increasing amount of data
uggest that by starting earlier, the so called ‘‘non-AIDS’’
iseases driving to mortality in the HAART era might be dra-
atically reduced. On top of the beneﬁts at the individual
evel, ART has been shown as a prevention tool by reduc-
ng the median viral load at the community level.Currently
vailable co formulations are the best options for ARV back-
one in naive patients. Issues such as childbearing potential
nd baseline resistance need to be taken into consideration
hen selecting a regimen. Controversies remain on whether
o use a PI or an NNRTI as the third drug in initial therapy,
articularly important in the presence of advanced disease.
he bottom line is that one size does not ﬁt for all in this
hallenging ﬁeld.
oi:10.1016/j.ijid.2010.02.2187
2.002
rug Resistance and Other Laboratory Monitoring Assays
n HIV infection
. Hirsch
Harvard Medical School, Boston, MA, USA
Although CD4 cell counts and plasma viral load assays
re the principal laboratory tests used to monitor the
rogress of HIV-1 infections, several other assays are assum-
ng increasing importance to adequately assess the beneﬁts
f antiretroviral therapy (ART) in infected individuals. The
ccessibility of such assays will vary greatly, depending on
he resources available to treat HIV infections.
Where testing capability exists, HIV drug resistance test-
ng is useful when patients enter care prior to initiating
herapy and again when considering change of regimens
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uring virologic failure. Genotypic assays are generally pre-
erred because of cost and rapidity, except in situations
here multiple ART regimens have been used, when phe-
otypic assays may be of value.
When abacavir is being considered as part of an ART
egimen, genetic screening for HLAB* 5701 is helpful to
educe the risk of severe abacavir hypersensitivity reac-
ions. These reactions, reported in 5-8% of white and 2-3%
f black patients occur primarily in individuals with the MHC
lass I allele HLA-B*5701. Individuals who screen positive for
LA-B*5701 should not receive abacavir.
When a CCR5 antagonist (e.g., maraviroc) is being con-
idered as part of an ART regimen, a coreceptor tropism
ssay is useful, since an agent of this class will only suppress
iruses that utilize this receptor (R5 viruses). CCR5 antago-
ists should not be used in individuals who carry primarily X4
r dual/mixed tropic viruses. Currently, the principal assay
vailable to measure HIV-1 tropism is phenotypic, though
enotypic tests are under study.
Although therapeutic drug monitoring is recommended
y some, its use remains controversial, and no clear-cut
ecommendations can be made regarding its utility.
oi:10.1016/j.ijid.2010.02.2188
2.003
pportunistic Infections and IRIS in the Era of HAART
. Miro
Hosp. Clinic - IDIBAPS. University of Barcelona, Barcelona,
pain
Despite the important advance that cART represents for
he prognosis of the HIV-1 infection, OIs continue to be an
mportant cause of morbidity and mortality in developed
ountries. This is due to late presentation (up to one-third
f new HIV-1 infections), lack of adherence to cART and
rophylaxis or virological failure of cART. In addition, OIs
re very common in developing countries, being tubercu-
osis (TB) the most common one. The ACTG A5164 results
ecommended to start cART during the ﬁrst 2 weeks after
tarting antimicrobial treatment for the OI (patients with
B were not included in this RCT). Some of these patients,
espite having an excellent viral and immune response to
ART, will present a paradoxical worsening of the OI known
s the immune reconstitution inﬂammatory syndrome (IRIS).
he microorganisms most commonly associated with IRIS are
ycobacteria, fungi, and herpes group viruses. The IRIS has
lso been reported in tumors, such as Kaposi sarcoma, and
auses autoimmune diseases. The percentage of patients
ho develop IRIS is variable. In cohort studies of patients
tarting cART, IRIS affects between 15% and 25%. In OIs series
ike TB the frequency is higher, and can reach 50%. Clini-
al effects of IRIS range from a mild, self-limiting illness to
evere morbidity and mortality. The lack of evidence-based
reatment guidelines poses challenges in the management
f these patients. Patients are generally recommended to
ontinue with cART and speciﬁc treatment against OIs.
djuvant nonsteroid anti-inﬂammatory drugs (NSAIDs) and
orticosteroids are commonly used. Corticosteroids have
emonstrated their usefulness in a recent clinical trial in
B patients. Surgery is necessary to debride abscesses.
s
o
dternational Congress on Infectious Diseases (ICID) Abstracts
n life-threatening cases, the possibility of interrupting
ART should be considered until the patient’s situation has
mproved. Clinical experience with immunosuppressors or
NF-alpha inhibitors is very limited.
oi:10.1016/j.ijid.2010.02.2189
2.004
hy are patients dying in the HAART Era?
. Katabira
Makerere University, Kampala, Uganda
NO ABSTRACT RECEIVED
oi:10.1016/j.ijid.2010.02.2190
iomarkers in infectious diseases (Invited Presenta-
ion)
3.001
linical Use of Biomarkers in the Diagnosis and Manage-
ent of CAP
. Ramirez
Hospital Universitario la Fe, Valencia, Spain
Community-acquired pneumonia (CAP) is a serious health
roblem worldwide with an annual incidence of 0.3-0.5%
n the adult population. Besides, CAP remains the leading
ause of death from infectious diseases. This justiﬁes the
nterest in studying all clinical aspects affecting CAP. A new
pproach is to evaluate biological markers of infection and
nﬂammation, as an expression of the hostˇıs inﬂammatory
esponse against the microorganism, in order to achieve
iagnosis, aetiology, progonosis and treatment informa-
ion. The most widely studied biomarkers have been C
eactive protein (CRP), procalcitonin (PCT) and cytokines.
ther biomarkers are now obtaining promising results. Most
uthors conclude that biomarkers can help in the diagno-
is of CAP. Fewer data analyse the capacity of biomarkers
n identiﬁying the potential causative agent and the best
esults have been settled down in children. Linked with the
bove mentioned, biomarkers, mainly PCT, have been used
uccesfully guiding antibiotic prescription in patients with
uspected CAP. Treatment guided by serum PCT was a safe
ay to avoid antibiotics, although economic savings were
vershadowed by PCT analysis costs. Approximately 10-15%
f patients hospitalised for CAP develop treatment failure
nd almost 6% may manifest rapidly progressive pneumonia,
t has been demonstrated that serum levels of biomarkers
an identify patients at risk of treatment failure and there-
ore could guide treatment handling. Clinical data scoring
ystems have been recognized as a useful tool to assess sta-
ility and prognosis of patients with CAP. Analysis of systemic
iomarkers in adition to clinical scores has shown to improve
ither the prediction of absence of severe complications
nd the 30-day mortality prediction by PSI or CURB65/CRB65
cales. Current data from literature seem to support the use
f biomarkers in the daily medical practice concerning CAP.
oi:10.1016/j.ijid.2010.02.2191
